J. R. Pereira

FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)

Robert Pirker, A. Szczęsna, Joachim von Pawel et al. · Journal of Clinical Oncology · 2008 · 173 citations

Medicine, Oncology, Pharmacology +17

Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patients

Jyoti D. Patel, J. R. Pereira, J. Chen et al. · Annals of Oncology · 2016 · 42 citations · Full text

Medicine, Oncology, Outcomes Research +13

[Lung cancer and the delay in the diagnosis: analysis of 300 cases].

P P Silva, J. R. Pereira, F.K Ikari et al. · PubMed · 1993 · 17 citations

Medicine, Internal Medicine, Oncology +17

Phase III study comparing cisplatin/vinorelbine plus cetuximab versus cisplatin/vinorelbine as first-line treatment for patients with epidermal growth factor (EGFR)-expressing advanced non-small cell lung cancer (NSCLC) (FLEX)

Joachim von Pawel, K. Park, J. R. Pereira et al. · Journal of Clinical Oncology · 2006 · 15 citations

Medicine, Oncology, Pharmacology +15

Does second-line therapy for non-small cell lung cancer (NSCLC) result in symptom palliation? Analysis of 484 patients from a randomized trial of pemetrexed vs docetaxel

Filippo de Marinis, J. R. Pereira, K. Park et al. · Journal of Clinical Oncology · 2004 · 11 citations

Medicine, Oncology, Pharmacotherapy +17